Work

988P Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)

Year: 2022

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.07.1115

Authors: S.S. Ramalingam, C. Zhou, T.M. Kim, J.C-H. Yang, G.J. Riely, T. Mekhail, D. Nguyen, M.R. Garcia Campelo, E. Felip, D. Misch, M. Kaur, V. Bunn, M. Lin, P. Zhang, P.A. Jänne

Institutions: Emory University, Shanghai Pulmonary Hospital, Seoul National University, Seoul National University Hospital, National Taiwan University, Memorial Sloan Kettering Cancer Center, AdventHealth Orlando, AdventHealth, City Of Hope National Medical Center, Complexo Hospitalario Universitario A Coruña, Vall d'Hebron Hospital Universitari, Helios Klinikum Emil von Behring, Takeda (United States), Dana-Farber Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4295817092

FWCI: 0.987

Cites:

Cited by: 7

Related to: 10